The global precision medicine market is expected to more than double over the next six years, reaching USD 237.28 billion by 2031 from USD 110.68 billion in 2025, according to market research firm Mordor Intelligence. The sector is projected to expand at a compound annual growth rate of 13.58% during this period, driven primarily by technological advances in artificial intelligence integration and biomarker development.
Key growth catalysts include the expanding adoption of next-generation sequencing technologies, which currently command over 35% of the market share, and the increasing deployment of targeted oncology therapies across healthcare systems. These technologies enable clinicians to tailor treatment approaches based on individual patient genetics and disease characteristics, improving therapeutic outcomes while potentially reducing healthcare costs through more efficient resource allocation.
Geographically, North America maintains its position as the market leader, while the Asia-Pacific region is emerging as a high-growth area. This regional expansion reflects growing healthcare infrastructure investments, increasing patient awareness of precision medicine approaches, and rising prevalence of chronic diseases in developing economies. The market's trajectory underscores the broader healthcare industry shift toward data-driven, individualized treatment paradigms.